Abstract
Because of increasing prevalence of multi-drug resistant (MDR) pathogens, there are many difficulties in the treatment of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP). It is known that patients with MDR pathogens have high mortality and morbidity. We need to know the current status of pathogens and antibiotics therapy for a proper choice of initial antibiotics to improve outcome of the patients.
Highlights
Because of increasing prevalence of multi-drug resistant (MDR) pathogens, there are many difficulties in the treatment of hospital-acquired pneumonia (HAP)/ventilatorassociated pneumonia (VAP)
This study was aimed at investigating the current pathogens and treatment of HAP/VAP in Korean ICUs
This study included patients who were admitted to adult medical ICUs with diagnosed as pneumonia developing at least 48 hours after admission or initiation of mechanical ventilation
Summary
Because of increasing prevalence of multi-drug resistant (MDR) pathogens, there are many difficulties in the treatment of hospital-acquired pneumonia (HAP)/ventilatorassociated pneumonia (VAP). Objectives This study was aimed at investigating the current pathogens and treatment of HAP/VAP in Korean ICUs. Methods A prospective, multicenter and observational study was conducted in six tertiary referral hospitals in Korea between August 1, 2012 and July 31, 2013. This study included patients who were admitted to adult medical ICUs with diagnosed as pneumonia developing at least 48 hours after admission or initiation of mechanical ventilation.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
